cording to
HCRI Founder and President Ronald L. Webster, Ph.D. "Many stuttering
therapies require long-term participation (a year or longer), are presented
by clinicians who have little direct experience with stuttering, and
typically yield unreliable results," said Webster. "In addition, fluency
enhancing devices that have garnered media attention, such as the
FluencyMaster and SpeechEasy, help with only about 25% of stuttering
cases," he added.
Conversely, Webster reports that 93% of HCRI clients master fluent
speech by the end of the 12-day intensive therapy program. Researchers
developed HFP after studying and treating more than 5,500 people who
stutter, ranging in age from 10 to 73. This third generation HCRI therapy
incorporates new knowledge of muscle movements that actively generate
fluent speech for each sound class in language and features additional
treatment innovations including:
-- Enhanced computer-based training techniques that make it easier for
clients to understand, learn and maintain details of muscle movements that
produce fluent speech;
-- An acoustically based biofeedback system that measures speech muscle
use in real time and signals clients whether or not they are using their
muscles correctly;
-- A virtual transfer module that facilitates the transition from
fluency skill use in the clinic to fluency skill use in daily life; and
-- Sophisticated performance tracking tools that determine therapy
progression and individualized support needs.
Future Potential for Global Treatment Access
HFP was built on a web-based platform and offers the potential to
deliver quality controlled stuttering therapy on a 24/7 basis to anyone in
the world with internet access. During the next two years, HCRI plans to
develop remote therapy administration over the web and partner with health
systems of countries where quality stuttering treatment is needed.
"The fact that we will be able to present stuttering
'/>"/>
SOURCE Hollins Communications Research Institute (HCRI) Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia2.
Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:3.
Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges4.
Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck5.
NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program6.
Advanced Life Sciences Added to Russell Microcap Index7.
Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 8.
SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 9.
ABT is the Only Source for Kelo-cote(R) Advanced Formula Scar Gel10.
SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 11.
Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)